Puma Biotechnology (PBYI) Total Current Liabilities (2011 - 2026)

Puma Biotechnology has reported Total Current Liabilities for 16 years, with the latest figure at $59.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 31.07% year-over-year to $59.7 million; the trailing twelve-month figure through Mar 2026 stood at $59.7 million (down 31.07% YoY), and the FY2025 full-year result was $81.3 million, down 15.46% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $59.7 million, down from $81.3 million in the prior quarter.
• The five-year high for Total Current Liabilities was $110.4 million in Q3 2024, with the low at $48.2 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $79.0 million across 5 years, with a median of $79.1 million in 2025.
• Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 58.79% — and 2024, when it surged 103.77%.
• Puma Biotechnology's Total Current Liabilities stood at $77.5 million in 2022, then climbed by 28.26% to $99.4 million in 2023, then fell by 3.29% to $96.1 million in 2024, then retreated by 15.46% to $81.3 million in 2025, then decreased by 26.48% to $59.7 million in 2026.
• The last three Total Current Liabilities figures came in at $59.7 million (Q1 2026), $81.3 million (Q4 2025), and $82.7 million (Q3 2025), per Business Quant data.